Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process, biosimilar medications are very similar to the original biologic version, but they’re not identical. There are currently five biosimilar drugs available for this medication, including:

  • Ahzantive (aflibercept-mrbb)
  • Enzeevu (aflibercept-abzv)
  • Pavblu (aflibercept-ayyh)
  • Yesafili (aflibercept-jbvf)
  • Opuviz (aflibercept-yszy)

Unlike the first three biosimilars, the last two — Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) — are newer options that a new healthcare team can prescribe in place of Eylea without consulting your original prescriber.

Because a doctor or another healthcare professional administers this medication in their office or clinic, Medicare Part B will cover eligible expenses.

If you need take-home medications after receiving Eylea, Part D prescription drug plans will cover eligible expenses. Private insurance companies administer Part D prescription drug plans on Medicare’s behalf. So drug costs and drug availability can vary by plan type and plan provider.

A doctor or another healthcare professional may prescribe Eylea (aflibercept) when medically necessary to slow progressive vision loss from the following conditions:

Medicare Part B covers limited outpatient medications, including those administered in a doctor’s office, hospital outpatient department, or other medical facility. And for Eylea (aflibercept), an injection that a doctor administers directly to the eye, coverage will usually be from Part B.

Once you’ve paid your Part B plan deductible, which is $257 in 2025, you’ll be responsible for a 20% coinsurance.

Part D drug plans cover take-home medications that you may need following Eylea (aflibercept).

Plans have three coverage stages, including the:

  • deductible stage
  • initial coverage stage
  • catastrophic coverage stage

The deductible stage

Not all Part D prescription drug plans have a deductible, but if yours does, you’ll join at this stage.

Once you’ve paid the plan deductible in full, the plan will begin paying its share of eligible costs.

Initial coverage stage

During this stage, you’ll pay a 25% coinsurance toward the cost of Eylea (aflibercept). This applies to both the brand name and generic versions of this and other medications.

In 2025, you’ll continue paying the 25% coinsurance until you’ve paid a total of $2,000. In 2026, this is expected to increase to $2,100.

Catastrophic coverage stage

During this stage, you’ll pay no further costs toward your prescription medications for the remaining calendar year.

You will receive an explanation of benefits (EOB) the month after your pharmacy bills your plan provider. The EOB will detail the following:

  • the prescriptions you’ve filled
  • the total amount the plan has paid
  • the total amount you’ve paid
  • the amount others have paid, such as another insurer (if applicable)
  • which coverage stage you’re at
  • what the plan has counted toward your total out-of-pocket expenses
  • the total amount the pharmacy has charged for your medications

Eylea is a brand-name biologic medication. Its active ingredient is aflibercept. The Food and Drug Administration (FDA) has approved this medication for the treatment of vision loss from:

Eylea (aflibercept) belongs to a group of medications called vascular endothelial growth factor (VEGF) inhibitors. Other drugs in this group include Avastin (bevacizumab) and Lucentis (ranibizumab).

While these three medications work similarly, they’re used in different ways. In fact, using Avastin (bevacizumab) for some of the listed eye conditions is specifically considered off-label use. This means the medication is not specifically approved for a condition for which a doctor may use it.

However, each of the three blocks VEGF production, which can cause abnormal blood vessels to grow in your eye, resulting in fluids that can leak. By blocking VEGF, these drugs can reduce fluid leakage into the center of your retina, which is called the macula.